clinical trial · NCT05164341
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Chiesi Farmaceutici S.p.A.·phase3·active not recruiting·n = 69
Partial LipodystrophymetreleptinPlacebo
brief summary
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
started
Dec 17, 2021
primary completion
Jul 21, 2026
completion
Oct 31, 2026
last updated
Jun 15, 2026
official title
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol